Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 291-130-9 | CAS number: 90341-97-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
Test material
- Reference substance name:
- 1-{[3-({[2-hydroxy-3-(2-methylphenoxy)propyl]amino}methyl)-3,5,5-trimethylcyclohexyl]amino}-3-(2-methylphenoxy)propan-2-ol
- Molecular formula:
- C29H42O4
- IUPAC Name:
- 1-{[3-({[2-hydroxy-3-(2-methylphenoxy)propyl]amino}methyl)-3,5,5-trimethylcyclohexyl]amino}-3-(2-methylphenoxy)propan-2-ol
- Reference substance name:
- 1-{[3-(aminomethyl)-3,5,5-trimethylcyclohexyl]amino}-3-(2-methylphenoxy)propan-2-ol
- Molecular formula:
- C19H29O2
- IUPAC Name:
- 1-{[3-(aminomethyl)-3,5,5-trimethylcyclohexyl]amino}-3-(2-methylphenoxy)propan-2-ol
- Reference substance name:
- 3-aminomethyl-3,5,5-trimethylcyclohexylamine
- EC Number:
- 220-666-8
- EC Name:
- 3-aminomethyl-3,5,5-trimethylcyclohexylamine
- Cas Number:
- 2855-13-2
- Molecular formula:
- C10H22N2
- IUPAC Name:
- 3-Aminomethyl-3,5,5-trimethylcyclohexanamine
- Reference substance name:
- 1-{[2-hydroxy-3-(2-methylphenoxy)propyl][3-({[2-hydroxy-3-(2-methylphenoxy)propyl]amino}methyl)-3,5,5-trimethylcyclohexyl]amino}-3-(2-methylphenoxy)propan-2-ol
- Molecular formula:
- C39H55N2O6
- IUPAC Name:
- 1-{[2-hydroxy-3-(2-methylphenoxy)propyl][3-({[2-hydroxy-3-(2-methylphenoxy)propyl]amino}methyl)-3,5,5-trimethylcyclohexyl]amino}-3-(2-methylphenoxy)propan-2-ol
- Test material form:
- liquid: viscous
Constituent 1
Constituent 2
Constituent 3
Constituent 4
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Animals were received from Charles River (Raleigh, NC, and Stone Ridge, NY) on 23 Mar 2017 and
13 Apr 2017. Following an acclimation period of at least five days, three male and six healthy,
non-pregnant and nulliparous female Sprague Dawley rats were assigned to treatment groups without
conscious bias.
The animals were born on 25 Jan 2017, 01 Feb 2017, and 15 Feb 2017. The pretest body weight range
was 394 - 427 grams for males and 198 - 219 grams for females. The weight variation of the animals
used did not exceed ±20% of the mean body weight of the previously dosed animals within a sex.
The animals were identified by cage notation and indelible body marks, and housed in suspended wire
cages; five per sex per cage prior to dosing and three per sex per cage following dosing. Absorbent
paper bedding was placed beneath the cages and changed at least three times per week. Fresh PMI Rat
Chow (Diet No. 5012) was freely available except for 16-20 hours prior to dosing. Water was available ad
libitum. The animal room, reserved exclusively for rats on acute tests, was temperature controlled, had a
12-hour light/dark cycle, and was kept clean and vermin free.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- The test article was used as received and the dose was based on the sample weight as calculated from the specific gravity. A single dose was administered orally by syringe and dosing needle.
- Doses:
- 300 - 2000 mg/kg b.w.
- No. of animals per sex per dose:
- Dose level of 2000 mg/kg was administered to three female rats. A dose level of 300 mg/kg was administered to two female and three male rats. One female rat received a dose level of 305 mg/kg.
- Control animals:
- no
- Details on study design:
- Type and Frequency of Observations
In Vivo - Animals were observed at 15 minutes, 1, 2 and 4 hours postdose and once daily for 14 days for
toxicity and pharmacological effects and twice daily for mortality. Body weights were recorded
immediately pretest, weekly, at death and at termination in the survivors. One female rat in the 300 mg/kg
dose group was also weighed on Day 5.
Post Mortem – All animals were humanely sacrificed using CO2 and were examined for gross pathology
following study termination.
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - < 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Two females were found dead and one female rat was euthanized due to moribund condition by Day 1 following the single 2000 mg/kg oral dose.
Two female and three male rats survived following a single 300 mg/kg oral dose. One female rat survived following a single 305 mg/kg oral dose. - Clinical signs:
- other: 2000 mg/kg - Abnormal physical signs including wetness and red staining of the nose/mouth area, diarrhea, soiling and wetness of the anogenital area, piloerection, negative righting reflex, sagging eyelids, and tremors were observed. 300 mg/kg - Abnormal
- Gross pathology:
- 2000 mg/kg - The gross necropsy revealed red staining on the nose/mouth area, yellow staining and soiling on the anogenital area, pale areas and darker than normal liver, darker than normal spleen, lighter than normal kidneys, and abnormalities of the gastrointestinal tract.
300 mg/kg - The gross necropsy revealed no observable abnormalities.
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The oral LD50 of Isophoronediamine-cresyl glycidyl ether adduct is greater than 300 mg/kg but less than 2000 mg/kg of body weight in rats and is considered to be in GHS Category 4.
- Executive summary:
The oral LD50 of Isophoronediamine-cresyl glycidyl ether adduct is greater than 300 mg/kg but less than 2000 mg/kg of body weight in rats and is considered to be in GHS Category 4.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
